GlassScriptPhysician profile
Kusha Rahgozar
NPI 1144751298
$42,309.88
in general payments reported to CMS, 2019-2025
6 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,126 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Grant: $18K · Food and Beverage: $3,912 · Education: $480 · Travel and Lodging: $1.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,000.00 |
| Grant | $17,916.67 |
| Food and Beverage | $3,911.55 |
| Education | $479.74 |
| Travel and Lodging | $1.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $20,903.93 | 2025 | Carto 3, Soundstar, Octaray Mapping Catheter |
| Boston Scientific Corporation | $12,901.05 | 2024-2025 | Accolade Sr, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Medtronic, INC. | $8,153.19 | 2024-2025 | Aurora Ev-Icd Mri Surescan, Selectsecure, Azure Xt Dr Mri Surescan |
| Biotronik INC. | $311.82 | 2024-2025 | Biomonitor, Acticor 7 Vr-T Dx, Pamira |
| Merck Sharp & Dohme LLC | $21.20 | 2024 | Verquvo |
| Chiesi USA, INC. | $18.69 | 2024 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kusha Rahgozar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.